Zum Beitrag „Neue Therapieoption für akute hepatische Porphyrien“

• Literatur

• 1 Stölzel U, Schuppan D. Neue Therapieoption für akute hepatische Porphyrien. Dtsch Med Wochenschr 2021; 146: 955-958
• 2 Bronisch O, Stauch T, Haverkamp T. et al. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic and clinical data of 62 families. Ann Hematol 2019; 98: 2683-2691
• 3 Lazareth H, Poli A, Bignon Y. et al. Renal function decline under therapy with small interfering RNA silencing ALAS1 for acute intermittent porphyria. Kidney Int Rep 2021; 6: 1904-1911
• 4 Petrides PE, Klein M, Schuhmann E. et al. Severe homocysteinemia in two Givosiran treated porphyria patients: is free heme deficiency the culprit?. Ann Hematol 2021; 100: 1685-1693
• 5 Ricci A, Marcacci M, Cuoghi C. et al. Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of ALAS1 modulation by siRNA therapy and its control by vitamin supplementation. Eur J Intern Med 2021;
• 6 Figueras J, Wijngaard R, Garcia-Villoria J. et al. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or Givosiran. J Inherit Metab Dis 2021;